GRANULES INDIA LTD.-$

Granules India Ltd has disclosed a significant shareholding change involving its promoter group. Mrs. Chigurupati Uma Devi, Mrs. Priyanka Chigurupati, Mrs. Pragnya Chigurupati, and Mr. Harsha Chigurupati, acting as persons acting in concert (PACs), have acquired a total of 2,49,82,906 equity shares. This acquisition occurred on September 16, 2026, through the conversion of warrants that were initially allotted on a preferential basis on February 23, 2026. The disclosure replaces a previous one dated September 25, 2026. The total holding of the promoter group, including these newly acquired shares, now stands at 31.08% of the total share capital.

Dr. Krishna Prasad Chigurupati and Persons Acting in Concert (PACs) have sold 1,72,00,000 equity shares of Granules India Limited. This sale represents 6.94% of the total share capital, with the holding of the promoter group decreasing from 38.02% to 31.08% before and after the transaction. The sale occurred on September 11, 2026, with 1,32,95,129 shares sold via block deal and 39,04,871 shares in the normal market.

Granules India Limited has disclosed the allotment of 2,49,82,906 warrants on a preferential basis to its promoter group, including Mrs. Chigurupati Uma Devi, Mrs. Priyanka Chigurupati, Mrs. Pragnya Chigurupati, and Mr. Harsha Chigurupati. These warrants are convertible into equity shares. The disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, details the pre-allotment holdings of the acquirers and persons acting in concert, which collectively stood at 38.82% of the total share capital. Post-allotment, the specific holdings of the individuals have increased, with Mrs. Chigurupati Uma Devi receiving 2,48,80,342 warrants (9.12%), Mrs. Priyanka Chigurupati 34,188 warrants (0.01%), Mrs. Pragnya Chigurupati 34,188 warrants (0.01%), and Mr. Harsha Chigurupati 34,188 warrants (0.01%).

Granules India Ltd has announced that its Board of Directors will convene on November 2, 2026. The primary agenda item for this meeting is to consider and approve the unaudited financial results for the second quarter and half-year ended September 30, 2026. In conjunction with this announcement, the company has also stated that the insider trading window will remain closed until November 4, 2026, to prevent any potential misuse of information.

Granules India Ltd has announced the incorporation of its wholly owned foreign subsidiary, TRITON FARMACEUTICA S.A. de C.V., in Mexico. This new entity, incorporated on October 22, 2026, is intended to manufacture, promote, sell, and distribute pharmaceuticals and related products within Mexico. The subsidiary has an authorized share capital of 4,50,000 shares of MXN 10.00 each. While it is a related party upon incorporation, the Promoter & Promoter Group of Granules India do not have any interest in this new entity. The subsidiary has not yet commenced business operations, and therefore, historical turnover and acquisition cost details are not applicable at this stage.

Granules India Limited has submitted an Abbreviated New Drug Application (ANDA) for Ruxolitinib Extended-Release Tablets with a Paragraph IV certification. The company believes it is eligible for first-to-file status, which could grant 180 days of generic drug exclusivity in the U.S. if confirmed by the FDA. This strategic move aligns with Granules India's objective to enhance its U.S. product portfolio with higher-value generics. The ANDA is subject to FDA review, and the company will provide further updates as required. This filing represents a significant step in their U.S. market strategy, focusing on technically and commercially attractive opportunities.

Granules India Ltd has released the transcript of a webinar held on September 29, 2026, detailing their "Granules India 2.0 Comprehensive Transformation Underway". The company outlined four key growth engines: controlled substances, complex generics and early market opportunities, oncologies, and peptide CDMO. These initiatives are built upon existing capabilities and aim to drive future growth across diverse products and markets. The strategy focuses on developing higher-value products, expanding geographic reach, and improving the portfolio mix, with a goal to translate investments into a substantially larger business with faster earnings growth over the next three to four years, while maintaining financial discipline. The company highlighted a shift towards a "3 first-to-file playbook" in R&D, emphasizing technical complexity, unmet patient needs, and market economics over sheer volume of filings. This has led to a significant increase in complex generics' contribution to revenue.

Granules India Ltd has announced the incorporation of its wholly owned foreign subsidiary, TRITON FARMACEUTICA DO BRASIL LTDA, in Brazil. This new entity is established to manufacture, promote, sell, and distribute pharmaceuticals and related products within Brazil. The incorporation is a strategic move to expand its global presence and market reach. The company has obtained prior approval from the Reserve Bank of India (RBI) under the automatic route for this incorporation. TRITON FARMACEUTICA DO BRASIL LTDA is a newly incorporated company and has not yet commenced business operations.

Uma Devi Chigurupati, part of the Promoter Group, has sold 2,48,80,342 shares of Granules India Limited, representing 9.12% of the total share capital. The transaction was conducted via the open market. Following the sale, her holding has reduced from 12.51% to 3.81% of the total share capital. The total equity share capital of the company before the sale was Rs. 24,77,96,921/-, and after the sale, it stands at Rs. 27,27,79,827/-.

Granules India Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from October 01, 2026, and will remain in effect until 48 hours after the declaration of the unaudited financial results for the second quarter and half-year ended September 30, 2026. The measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations 2015 and the company's internal code of conduct, aimed at preventing insider trading.